Apoptoctic signaling Gabriel Gil

Font A^*, Mellado B^*, Climent MA, Virizuela JA, Oudard S, Puente J, Castellano D, González del Alba A, Pinto A, Morales-Barrera R, Rodríguez-Vida A, Fernandez PL, Teixido C, Jares P, Aldecoa I, Gibson N, Solca F, Mondal S, Lorence RM, Serra J, Real FX^*. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1). Br J Cancer 2024; 130(3): 434-441.
Zamora V, Garin O^*, Suárez JF, Gutiérrez C, Guedea F, Cabrera P, Castells M, Herruzo I, Fumadó L, Samper P, Ferrer C, Regis L, Pont A, Ferrer M^*, Multicentric Spanish Group of Clinically Localized Prostate Cancer. Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures. Clin Transl Radiat Oncol . 2024; 44: 100694 (Acceptat).